LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers

Archives of Pharmacal Research

Volumn 28, Issue 4, 2005, Pages 463-468

  Ji, Hye Yun ^a   Ja, Hye Myung ^a   Hye, Jin Kim ^a   Lee, Sibeum ^a   Park, Jong Sei ^b   Kim, Won ^b   Lee, Eun Hee ^c   Cheol, Jin Moon ^c   Hwang, Sung Joo ^a  

^a Chungnam National University   (South Korea)

^b KSBC Bldg   (South Korea)

^c Green Cross Company   (South Korea)

Author keywords

Bioavailability; Human plasma; Imidapril hydrochloride; Quadruple mass spectrometry; SPE

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; IMIDAZOLIDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TABLET; VALIDATION STUDY;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; IMIDAZOLIDINES; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TABLETS;

EID: 22844438747     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02977677     Document Type: Article

References (10)

1. Belal, F., Al -Zaagi, I. A., Gadkariem, E. A., and Abounassif, M. A., A stability-indicating LC method for the simultaneous determination of ramipril and hydrochlorothiazide in dosage forms. J. Pharm. Biomed. Anal., 24, 335-342 (2001).
2. Bonazzi, D., Gotti, R., Andrisano, V., and Cavrini, V., Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC). J. Pharm. Biomed. Anal., 16, 431-438 (1997).
3. Harder, S., Thurmann, P. A., and Ungethum, W., Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br. J. Clin. Pharmacol., 45, 377-380 (1998).
4. Lee, Y. J., Jung, S. J., and Shim, C. K., K-BE Test 2002 for window, Version 1.2.1. (2002).
5. Mabuchi, M., Kano, Y., Fukuyama, T., and Kondo, T., Determination of imidapril and imidaprilat in human plasma by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. B, 734, 145-153 (1999).
6. Tanaka, H. Y., Yoneyama, Sugawara, M., Umeda, I., and Ohta, Y., Enzyme immunoassay discrimination of a new angiotensin-converting enzyme (ACE) inhibitor, cilazapril, and its active metabolite. J. Pharmaceutical Science, 76, 224-227 (1987).
7. Tipnis, V. and Rakhit, A., Determination of pentopril, an angiotensin converting enzyme inhibitor, and its active metabolite in urine. J. Chromatogr.:Biomedical Application, 345, 396-401 (1985).
8. Yamanaka, K., Morikawa, S., Murata, K., Bano, K., Sato, T., Takai, T., Suzuki, T., Mizobe, M., Ito, M., and Ishibashi, K., Radioimmunoassay for imidapril, a new angiotensin-converting enzyme inhibitor, and imidaprilat, its active metabolite, in human plasma and urine. J. Pharm. Biomed. Anal., 14, 281-287 (1996).
9. Yamanaka, K., Takehara, N., Murata, K., Banno, K., and Sato, T., Pharmacokinetic and pharmacodynamic study of imidaprilat, and active metabolite of imidapril, a new angiotensin-coverting enzyme inhibitor, in spontaneously hypertensive rats. J. Pharm. Biomed. Anal., 15, 1851-1859 (1997).
10. Zhu, Z., Vachareau, A., and Neirinck, L., Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma. J. Chromatogr. B, 779, 297-306 (2002).